Top

Published in:

01-11-2007 | Review

Aromatase inhibitors and cardiac toxicity: getting to the heart of the matter

Authors: Sonal Gandhi, Sunil Verma

Published in: Breast Cancer Research and Treatment | Issue 1/2007

Abstract

Recent advances in breast cancer treatment include the advent of aromatase inhibitors (AIs) in the adjuvant setting with better efficacy and toxicity profiles than tamoxifen. However, AIs generally do not improve lipid profile as tamoxifen does, and there has been suggestion of increased cardiovascular risk with AI use. This has become an area of concern, particularly in light of the view that tamoxifen may protect against cardiovascular disease. This review of the current literature and updated trial data examines the effect both AIs and tamoxifen have on lipids and cardiovascular risk. It also highlights the importance of interpreting such data within the larger context of cardiovascular health in postmenopausal women.

Clemons M, Coleman RE, Verma S (2004) Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard? Cancer Treat Rev 30:325–332PubMedCrossRef

BIG-198 Collaborative Group (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. NEJM 355(26):2747–2757CrossRef

ATAC trialists Group (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Cancer 98(9):1802–1810CrossRef

Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. NEJM 350(11):1081–1092PubMedCrossRef

Jakesz R, Jonat W, Gnant M et al (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of the ABCSG trial 8 and ARNO 95 trial. Lancet 366:455–462PubMedCrossRef

Boccardo F, Rubagotti A, Guglielmini P et al (2006) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 17(Suppl 7):vii10–vii14PubMedCrossRef

Goss PE, Ingle JN, Martino S et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. NEJM 349(19):1793–1802PubMedCrossRef

Catalitotti L, Buzdar AU, Noguchi S et al (2006) Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the preoperative “Arimidex” compared to Tamoxifen (PROACT) trial. Cancer 106(10):2095–2103CrossRef

Grey AB, Stapleton JP, Evans MC et al (1995) The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab 80(11):3191–3195PubMedCrossRef

10.

Nabholtz JM, Gligorov J (2006) Cardiovascular safety profiles of aromatase inhibitors: a comparative review. Drug Saf 29(9):785–801PubMedCrossRef

11.

Venturini M, Del Mastro L (2006) Safety of adjuvant aromatase inhibitor therapy. Cancer Treat Rev 32(7):548–556PubMedCrossRef

12.

Pritchard KI, Abramson BL (2006) Cardiovascular health and aromatase inhibitors. Drugs 66(13):1727–1740PubMedCrossRef

13.

Howell A, Cuzick J (2005) Vascular effects of aromatase inhibitors: data from clinical trials. J Steroid Biochem Mol Biol 95(1–5):143–149PubMedCrossRef

14.

Esteva FJ, Hortobagyi GN (2006) Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women. Breast 15(3):301–312PubMedCrossRef

15.

Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. NEJM 348(24):2432–2442CrossRef

16.

Morise AP (2006) Assessment of estrogen status as a marker of prognosis in women with symptoms of suspected coronary artery disease presenting for stress testing. Am J Cardiol 97(3):367–371PubMedCrossRef

17.

The Womens Health Initiative Steering Committee (2001) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy, The Women’s Health Initiative Randomized Trial. JAMA 291:1701–1712

18.

Writing Group for the Womens Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288:321–333

19.

Gouva L, Tsatsoulis A (2004) The role of estrogens in cardiovascular disease in the aftermath of clinical trials. Hormones (Athens) 3(3):171–183

20.

Walsh BW, Schiff I, Rosner B et al (1991) Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 325(17):1196–1204PubMedCrossRef

21.

Binder EF, Williams DB, Schechtam KB et al (2001) Effects of hormone replacement therapy on serum lipid in elderly women; a randomized placebo-controlled trial. Ann Intern Med 134(9 Pt 1):754–760PubMed

22.

Kim CJ, Min Yk, Ryu WS et al (1994) Effects of hormone replacement therapy on lipoprotein(a) and lipids in postmenopausal women. Arterioscler Thromb 14(2):275–281PubMed

23.

Gordon DJ, Probstfield JL, Garrison RJ et al (1989) High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79:8–15PubMed

24.

Lipid Research Clinics Program (1984) The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251:365–374

25.

Austin MA, Hokanson JE, Edwards KL (1998) Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 81(4A):7B–12BPubMedCrossRef

26.

Gierach GL, Johnson BD, Bairey MC et al (2006) Hypertension, menopause, and coronary artery disease risk in the Women’s Ischemia Syndrome Evaluation (WISE) study. J Am Coll Cardiol 47(3 Suppl):S50–S58PubMedCrossRef

27.

D’Agostino RB, Grundy S, Sullivan LM et al (2001) Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 286(2):180–187PubMedCrossRef

28.

Yusuf S, Hawken S, Ounpuu S et al (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet 364(9438):937–952PubMedCrossRef

29.

Wilson PW, D’Agostino RB, Levy D et al (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97(18):1837–1847PubMed

30.

Cuzick J (1992) Long term effects of tamoxifen. Biological effects of tamoxifen Working Party. Eur J Cancer 29A(1):15–21PubMed

31.

Gupta S, Tandon VR, Kapoor B et al (2006) Effects of tamoxifen therapy on plasma lipid profile in patients of breast cancer. J Assoc Physicians India 54:183–186PubMed

32.

Joensuu H, Holli K, Oksanen H et al (2000) Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer. Breast Cancer Res Treat 63(3):225–234PubMedCrossRef

33.

McDonald CC, Stewart HJ (1991) Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. BMJ 303:435–437PubMedCrossRef

34.

McDonald CC, Alexander FE, Whyte BW et al (1995) Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial. BMJ 311:977–980PubMed

35.

Rutqvist LE, Mattsson A (1993) Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst 85(17):1398–1406PubMedCrossRef

36.

Nordenskjold B, Rosell J, Rutqvist LE et al (2005) Coronary heart disease mortality after 5 years of tamoxifen therapy: results from a randomized trial. J Natl Cancer Inst 97(21):1609–1610PubMedCrossRef

37.

Costantino JP, Kuller LH, Ives DG et al (1997) Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst 89:776–782PubMedCrossRef

38.

Ries SE, Costantino JP, Wickerman DL et al (2001) Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. J Natl Cancer Inst 93:16–21CrossRef

39.

Braithwaite RS, Chlebowski RT, Lau J et al (2003) Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 18:937–947PubMedCrossRef

40.

Wasan KM, Goss PE, Pritchard PH et al (2005) The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol 16(5):707–715PubMedCrossRef

41.

Atalay G, Dirix L, Biganzoli L et al (2004) The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, ‘Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients’. Ann Oncol 15(2):211–217PubMedCrossRef

42.

Markopoulos C, Polychronis A, Zobolas V et al (2005) The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek substudy. Breast Cancer Res Treat 93(1):61–66PubMedCrossRef

43.

Lonning PE, Geisler J, Krag LE et al (2005) Effects of exemestane administered for 2 years versus placebo on bone mineral density, biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 23(22):5126–5137PubMedCrossRef

44.

Arbuck SG, Ivy SP, Setser A et al (1999) The Revised Common Toxicity Criteria Version 2.0: National Cancer Institute, CTEP Website. http://ctep.info.nih.gov. Cited 5th July 2006

45.

Lerner DJ, Kannel WB (1986) Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 111(2):383–390PubMedCrossRef

46.

ATAC trialists Group (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62CrossRef

47.

Coombes RC, Paridaens R, Jassem J et al (2006) First mature analysis of the Intergroup Exemestane Study. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I 24(Suppl 18S): LBA527

48.

Boccardo F, Rubagotti A, Guglielmini P et al (2006) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 17(Suppl 7):vii10-vii14PubMedCrossRef

49.

Almeida S, Hutz MH (2006) Estrogen receptor I gene polymorphisms and coronary artery disease in the Brazilian population. J Med Biol Res 39(4):447–454

Title: Aromatase inhibitors and cardiac toxicity: getting to the heart of the matter
Authors: Sonal Gandhi
Sunil Verma
Publication date: 01-11-2007
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2007
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-006-9470-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2007

Changes in shoulder muscle size and activity following treatment for breast cancer

A decade of breast cancer screening in The Netherlands: trends in the preoperative diagnosis of breast cancer

Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre

Two-stage case-control study of common ATM gene variants in relation to breast cancer risk

Reduction in proliferation with six months of letrozole in women on hormone replacement therapy

Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer